Vivus Articles
Positive CHMP recommendations for Astellas Xtandi, Roche's Erivedge, as well MACI, Nuedexta and Spedra
28 April 2013
EMA confirms negative view on Vivus' obesity drug Qsiva after appeal
22 February 2013
Express Scripts adds Vivus' Qsymia to its standard benefits program
20 December 2012
Vivus gets formal "No" from EMA panel on obesity drug
19 October 2012
New uses of Cialis, Votubia, Galvus, Eucreas and Eliquis backed by CHMP, but not Qsiva
24 September 2012
Vivus debuts weight-loss pill Qsymia on US market
19 September 2012
US FDA approves second diet pill, Vivus' Qsymia
18 July 2012
US FDA clears new ED drug Stendra
30 April 2012
Vivus says FDA has delayed Qnexa PDUFA date
10 April 2012
FDA advisory panel backs approval of Qnexa
23 February 2012
FDA updates on obesity drug candidates
11 January 2012
Obesity drug market set to grow to $2.6 billion by 2020, says DR report
27 September 2011
Vivus agrees pathway with US FDA for re-submission of Qnexa NDA
16 September 2011
ADA meeting hears news of XOMA’s new classes of insulin receptor-regulating Ab and Vivus’ Qnexa
27 June 2011
Topiramate carries risk of birth defect, says US FDA
7 March 2011
US FDA approves additional medical indication for Bristol-Myers Squibb’s Sprycel; clears Sunovion’s Latuda; further delays Vivus’ Qnexa
29 October 2010
Vivus returns rights to develop Luramist to Acrux
1 April 2010
Showing 1-35 of 35 articles
- 1
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Is the diabetes market facing a blockbuster-free future?
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
